# A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Source: https://onco.cc/trials/nct07652073/  
OnCo record `nct07652073` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of DAT-2645 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.

## Summary

A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer is a phase 2 interventional study registered as NCT07652073 by Danatlas Pharmaceuticals Co., Ltd, with 30 participants planned, started 2026-06-15. Conditions recorded: Advanced or Metastatic Ovarian Cancer. Interventions recorded: DAT-2645 tablet.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07652073
- Phase: 2
- Setting: A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1/2 Deleterious Mutations or HRD-Positive Advanced/Metastatic Ovarian Cancer
- Sponsor: Danatlas Pharmaceuticals Co., Ltd
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07652073: https://clinicaltrials.gov/study/NCT07652073

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [DAT-2645](https://onco.cc/drugs/dat-2645/)
- companies: [Danatlas Pharmaceuticals](https://onco.cc/companies/danatlas-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct07652073.json